Pharmacokinetics of single oral dose of pimobendan in hispaniolan amazon parrots (amazona ventralis)

David Guzman, Hugues Beaufrère, Butch Kukanich, Steven A. Barker, João Brandão, Joanne R Paul-Murphy, Thomas N. Tully

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Pimobendan is a phosphodiesterase (PDE) inhibitor and calcium sensitizer with inotropic, lusitropic, and rasodilator properties used in the treatment of congestive heart failure. The mechanism of action is by inhibition of PDE III and V and by increasing intracellular calcium sensitivity in the cardiac myocardium. Pharmacokinetic and pharmacodynamic studies have been published in humans, dogs, and cats, but there are no studies in avian species. Pimobendan has been used in birds at the empirical dosage of 0.25 mg/kg q12h. To determine the pharmacokinetic parameters of pimobendan in Hispaniolan Amazon parrots (Amazona ventralis), 3 pilot studies with 2 birds, each receiving 1, 3, and 10 mg/kg PO, provided the basis for the pivotal trials with 6 birds, each receiving 10 mg/kg PO using 2 different suspensions. Blood samples were obtained at 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, and 18 hours after drug administration. Plasma concentrations were determined by liquid chromatography-tandem mass spectrometry (HPLC/MS) by use of electrospray ionization. Because of the erratic and low concentrations of pimobendan, pharmacokinetic parameters were calculated using naive averaged analysis. Plasma concentrations after commercial pimobendan tablet suspension at 10 mg/kg reached a Cmax of 8.26 ng/mL at 3 hours with a terminal half-life of 2.1 hours, while concentrations after the bulk chemical suspension reached a Cmax of 1.28 ng/mL at 12 hours and had a terminal half-life of 2.3 hours. Further studies evaluating the effect of oral pimobendan in parrots are needed.

Original languageEnglish (US)
Pages (from-to)95-101
Number of pages7
JournalJournal of Avian Medicine and Surgery
Volume28
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Amazona
parrots
pharmacokinetics
mouth
Pharmacokinetics
half life
birds
dosage
Birds
calcium
Suspensions
pharmacology
heart failure
myocardium
ionization
liquid chromatography
Half-Life
mechanism of action
high performance liquid chromatography
Type 3 Cyclic Nucleotide Phosphodiesterases

Keywords

  • Amazona ventralis
  • avian
  • congestive heart failure
  • Hispaniolan Amazon parrots
  • inotropic
  • pharmacokinetic
  • pimobendan
  • psittacine

ASJC Scopus subject areas

  • Small Animals

Cite this

Pharmacokinetics of single oral dose of pimobendan in hispaniolan amazon parrots (amazona ventralis). / Guzman, David; Beaufrère, Hugues; Kukanich, Butch; Barker, Steven A.; Brandão, João; Paul-Murphy, Joanne R; Tully, Thomas N.

In: Journal of Avian Medicine and Surgery, Vol. 28, No. 2, 2014, p. 95-101.

Research output: Contribution to journalArticle

Guzman, David ; Beaufrère, Hugues ; Kukanich, Butch ; Barker, Steven A. ; Brandão, João ; Paul-Murphy, Joanne R ; Tully, Thomas N. / Pharmacokinetics of single oral dose of pimobendan in hispaniolan amazon parrots (amazona ventralis). In: Journal of Avian Medicine and Surgery. 2014 ; Vol. 28, No. 2. pp. 95-101.
@article{1728597c1ddc4d0eb90168a7723db806,
title = "Pharmacokinetics of single oral dose of pimobendan in hispaniolan amazon parrots (amazona ventralis)",
abstract = "Pimobendan is a phosphodiesterase (PDE) inhibitor and calcium sensitizer with inotropic, lusitropic, and rasodilator properties used in the treatment of congestive heart failure. The mechanism of action is by inhibition of PDE III and V and by increasing intracellular calcium sensitivity in the cardiac myocardium. Pharmacokinetic and pharmacodynamic studies have been published in humans, dogs, and cats, but there are no studies in avian species. Pimobendan has been used in birds at the empirical dosage of 0.25 mg/kg q12h. To determine the pharmacokinetic parameters of pimobendan in Hispaniolan Amazon parrots (Amazona ventralis), 3 pilot studies with 2 birds, each receiving 1, 3, and 10 mg/kg PO, provided the basis for the pivotal trials with 6 birds, each receiving 10 mg/kg PO using 2 different suspensions. Blood samples were obtained at 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, and 18 hours after drug administration. Plasma concentrations were determined by liquid chromatography-tandem mass spectrometry (HPLC/MS) by use of electrospray ionization. Because of the erratic and low concentrations of pimobendan, pharmacokinetic parameters were calculated using naive averaged analysis. Plasma concentrations after commercial pimobendan tablet suspension at 10 mg/kg reached a Cmax of 8.26 ng/mL at 3 hours with a terminal half-life of 2.1 hours, while concentrations after the bulk chemical suspension reached a Cmax of 1.28 ng/mL at 12 hours and had a terminal half-life of 2.3 hours. Further studies evaluating the effect of oral pimobendan in parrots are needed.",
keywords = "Amazona ventralis, avian, congestive heart failure, Hispaniolan Amazon parrots, inotropic, pharmacokinetic, pimobendan, psittacine",
author = "David Guzman and Hugues Beaufr{\`e}re and Butch Kukanich and Barker, {Steven A.} and Jo{\~a}o Brand{\~a}o and Paul-Murphy, {Joanne R} and Tully, {Thomas N.}",
year = "2014",
doi = "10.1647/2012-061",
language = "English (US)",
volume = "28",
pages = "95--101",
journal = "Journal of Avian Medicine and Surgery",
issn = "1082-6742",
publisher = "Association of Avian Veterinarians",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics of single oral dose of pimobendan in hispaniolan amazon parrots (amazona ventralis)

AU - Guzman, David

AU - Beaufrère, Hugues

AU - Kukanich, Butch

AU - Barker, Steven A.

AU - Brandão, João

AU - Paul-Murphy, Joanne R

AU - Tully, Thomas N.

PY - 2014

Y1 - 2014

N2 - Pimobendan is a phosphodiesterase (PDE) inhibitor and calcium sensitizer with inotropic, lusitropic, and rasodilator properties used in the treatment of congestive heart failure. The mechanism of action is by inhibition of PDE III and V and by increasing intracellular calcium sensitivity in the cardiac myocardium. Pharmacokinetic and pharmacodynamic studies have been published in humans, dogs, and cats, but there are no studies in avian species. Pimobendan has been used in birds at the empirical dosage of 0.25 mg/kg q12h. To determine the pharmacokinetic parameters of pimobendan in Hispaniolan Amazon parrots (Amazona ventralis), 3 pilot studies with 2 birds, each receiving 1, 3, and 10 mg/kg PO, provided the basis for the pivotal trials with 6 birds, each receiving 10 mg/kg PO using 2 different suspensions. Blood samples were obtained at 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, and 18 hours after drug administration. Plasma concentrations were determined by liquid chromatography-tandem mass spectrometry (HPLC/MS) by use of electrospray ionization. Because of the erratic and low concentrations of pimobendan, pharmacokinetic parameters were calculated using naive averaged analysis. Plasma concentrations after commercial pimobendan tablet suspension at 10 mg/kg reached a Cmax of 8.26 ng/mL at 3 hours with a terminal half-life of 2.1 hours, while concentrations after the bulk chemical suspension reached a Cmax of 1.28 ng/mL at 12 hours and had a terminal half-life of 2.3 hours. Further studies evaluating the effect of oral pimobendan in parrots are needed.

AB - Pimobendan is a phosphodiesterase (PDE) inhibitor and calcium sensitizer with inotropic, lusitropic, and rasodilator properties used in the treatment of congestive heart failure. The mechanism of action is by inhibition of PDE III and V and by increasing intracellular calcium sensitivity in the cardiac myocardium. Pharmacokinetic and pharmacodynamic studies have been published in humans, dogs, and cats, but there are no studies in avian species. Pimobendan has been used in birds at the empirical dosage of 0.25 mg/kg q12h. To determine the pharmacokinetic parameters of pimobendan in Hispaniolan Amazon parrots (Amazona ventralis), 3 pilot studies with 2 birds, each receiving 1, 3, and 10 mg/kg PO, provided the basis for the pivotal trials with 6 birds, each receiving 10 mg/kg PO using 2 different suspensions. Blood samples were obtained at 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, and 18 hours after drug administration. Plasma concentrations were determined by liquid chromatography-tandem mass spectrometry (HPLC/MS) by use of electrospray ionization. Because of the erratic and low concentrations of pimobendan, pharmacokinetic parameters were calculated using naive averaged analysis. Plasma concentrations after commercial pimobendan tablet suspension at 10 mg/kg reached a Cmax of 8.26 ng/mL at 3 hours with a terminal half-life of 2.1 hours, while concentrations after the bulk chemical suspension reached a Cmax of 1.28 ng/mL at 12 hours and had a terminal half-life of 2.3 hours. Further studies evaluating the effect of oral pimobendan in parrots are needed.

KW - Amazona ventralis

KW - avian

KW - congestive heart failure

KW - Hispaniolan Amazon parrots

KW - inotropic

KW - pharmacokinetic

KW - pimobendan

KW - psittacine

UR - http://www.scopus.com/inward/record.url?scp=84902660538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902660538&partnerID=8YFLogxK

U2 - 10.1647/2012-061

DO - 10.1647/2012-061

M3 - Article

C2 - 25115037

AN - SCOPUS:84902660538

VL - 28

SP - 95

EP - 101

JO - Journal of Avian Medicine and Surgery

JF - Journal of Avian Medicine and Surgery

SN - 1082-6742

IS - 2

ER -